Prometheus Biosciences earnings beat by $0.05, revenue topped estimates

  • Investing.com
Prometheus Biosciences earnings beat by $0.05, revenue topped estimates
Credit: © Reuters.

Investing.com - Prometheus Biosciences (NASDAQ: RXDX) reported first quarter EPS of $-0.86, $0.05 better than the analyst estimate of $-0.91. Revenue for the quarter came in at $1.11M versus the consensus estimate of $550K.

Prometheus Biosciences's stock price closed at $194.40. It is up 65.43% in the last 3 months and up 691.21% in the last 12 months.

Prometheus Biosciences saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Prometheus Biosciences's stock price’s past reactions to earnings here.

According to InvestingPro, Prometheus Biosciences's Financial Health score is "fair performance".

Check out Prometheus Biosciences's recent earnings performance , and Prometheus Biosciences's financials here.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100

Related Articles